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Background: Fructose acutely raises serum uric acid in normal subjects, but the effect in subjects with metabolic
syndrome or subjects with chronic kidney disease is unknown. The aim of the study was to evaluate changes in serum
uric acid during the fructose tolerance test in patients with chronic kidney disease, metabolic syndrome with comparison
to healthy controls.
Methods: Studies were performed in 36 subjects with obesity (body mass index >30) and metabolic syndrome, 14
patients with stage 3 chronic kidney disease, and 25 healthy volunteers. The fructose tolerance test was performed in
each patient. The change in serum uric acid during the fructose challenge was correlated with baseline ambulatory
blood pressure, serum uric acid, metabolic, and inflammatory markers, and target organ injury including carotid intima
media thickness and renal resistive index (determined by Doppler).
Results: Absolute serum uric acid values were highest in the chronic kidney disease group, followed by the metabolic
syndrome and then healthy controls. Similar increases in serum uric acid in response to the fructose tolerance test was
observed in all three groups, but the greatest percent rise was observed in healthy controls compared to the other two
groups. No significant association was shown between the relative rise in uric acid and clinical or inflammatory
parameters associated with kidney disease (albuminuria, eGFR) or metabolic syndrome.
Conclusions: Subjects with chronic kidney disease and metabolic syndrome have higher absolute uric acid values
following a fructose tolerance test, but show a relatively smaller percent increase in serum uric acid. Changes in serum
uric acid during the fructose tolerance test did not correlate with changes in metabolic parameters, inflammatory
mediators or with target organ injury. These studies suggest that acute changes in serum uric acid in response to
fructose do not predict the metabolic phenotype or presence of inflammatory mediators in subjects with obesity,
metabolic syndrome or chronic kidney disease.
Trial registration: The study was registered in ClinicalTrials.gov. Identifier : NCT01332526.
www.register.clinicaltrials.gov/01332526
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Excesive consumption of added sugars such as high-
fructose corn syrup (HFCS) increases the risk for cardio-
vascular diseases, the metabolic syndrome, type 2 diabetes,
dyslipidemia, fatty liver and chronic kidney disease (CKD)
[1-5]. Fructose, a major component of added sugars, is
relatively unique among carbohydrates in its ability to in-
crease uric acid generation, which occurs during the me-
tabolism of fructose. The rise in serum uric acid has been
proposed to be one mechanism by which fructose may in-
crease the risk for hypertension and CKD progression
[6-8]. Fructose feeding with increased serum uric acid has
been shown in rats to cause an afferent arteriolopathy,
glomerular hypertension, glomerulosclerosis and tubu-
lointerstitial fibrosis [9-12].
The ability of fructose to raise serum uric acid has led
to the development of a fructose tolerance test (FTT), in
which an oral load of fructose is followed by measure-
ment of serum uric acid over one to two hours. There is
some evidence that the FTT is enhanced in subjects on
a high fructose diet, as well as in subjects with hyperten-
sion [13]. Less is known about the changes of serum uric
acid that occur during oral FTT in subjects with CKD
and/or the metabolic syndrome. Anderstam analyzed the
effect of 75 g of fructose load on serum uric acid in
hemodialysis patients in comparison to healthy controls.
They reported stable serum uric acid levels during the
test in healthy individuals but a significant increase by
10% in hemodialysis patients at 240 minutes after fruc-
tose intake [14]. Here we compared the effects of FTT
in subjects with obesity and metabolic syndrome, sub-
jects with CKD and healthy controls. We also tested the
hypothesis that the change in serum uric acid in re-
sponse to fructose might correlated with the metabolic
phenotype, the degree of renal injury, the presence of in-
flammation or the presence of target organ injury.Methods
Thirty-six patients with body mass index (BMI) >30 and
metabolic syndrome (according to NCEP ATP III cri-
teria) (mean age 53 ± 8; F-19,M-17); 14 patients with
CKD stage 3 (mean age 67 ± 10; F-9, M-5) and 25
healthy volunteers (mean age 53 ± 10; F-15, M-10) were
studied. Causes of CKD were: hypertensive nephropathy
in 8 subjects, ischemic nephropathy in 3, chronic glom-
erulonephritis in 2, and chronic tubulointerstitial neph-
ritis in 1.Inclusion criteria
Age 18–78 years, BMI >30 with metabolic syndrome
(NCEP ATP III), CKD stage 3 with proteinuria less than
3.5 g per day, with a blood pressure <140/90 mmHg/.Exclusion criteria
Fructose intolerance, BMI < 18, presence of diabetes
mellitus, symptomatic gout defined as an acute inflam-
matory arthritis in the last 3 months, or presence of
chronic inflammatory diseases (including systemic lupus
erythematosus - SLE, chronic inflammatory bowel dis-
ease, and rheumatoid arthritis) or use o immunosup-
pressive treatment, angiotensin converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs),
or allopurinol.
Laboratory analyses
Morning blood samples were evaluated after an overnight
fast for creatinine, uric acid, sodium, potassium, glucose,
fructose, insulin (insulin ELISA), triglycerides, HDL, LDL
cholesterol, calcium, phosphorus, N-acetyl-beta-(D)-glu-
cosaminidase (NAG) was assayed by colorimetric method
(Roche Diagnostics), high sensitvity C reactive protein
(hsCRP) was measured using the BN II System nephelom-
eter (High Sensitivity CRP; Siemens Healthcare Diagnos-
tics, IL, USA), monocyte chemoattractant protein-1
(MCP-1); was assayed using Human ELISA Kit, erythro-
poietin (EPO) was assayed using Human Erythropoetin
ELISA Kit) tissue necrosis factor-alpha (TNF-alpha) was
assayed using TNF-alpha Human ELISA Kit, tissue growth
factor-beta (TGF-beta) was assayed using TGF-beta
Human ELISA Kit, inducible nitric oxide synthase (iNOS)
was assayed using Human inducible nitric oxide synthase,
endothelial human nitric synthase (eNOS) was assayed
using Human Endothelial nitric oxide synthase ELISA
kit, endothelin-1 was assayed using Human Endothelin
1 ELISA Kit and cystatin C was assayed using human
Cystatin C Quantikine ELISA Kit.
The same day a fructose tolerance test (FTT) was con-
ducted in all investigated patients and controls. The
standard FTT was performed after overnight fasting ac-
cording to the same protocol. After giving 1 gram/kg
body weight of fructose orally, blood was collected at 0,
30, 60 and 120 min for serum uric acid. The uric acid
area under the curve was calculated. The day before
blood sampling and the FFT test, a 24-hr urine collection
for: sodium, calcium, phosphorus, creatinine, uric acid,
and albumin was performed. Before the urine collection
was initiated, ambulatory blood pressure (ABPM) was ini-
tiated, and anthropometric measurements including BMI
and waist circumference were performed. Target organ
damage was also assessed, including carotid ultrasound
to measure intima medial thickness (IMT), renal artery
Doppler to measure renal resistive index (RI), and severity
of renal injury (albuminuria, eGFR). These measurements
were performed the day before the FTT.
The study protocol was approved by the local Bio-
ethical Committee of Collegium Medicum in Bydgoszcz,
the Nicolaus Copernicus University in Toruń in 2011
Table 1 Laboratory and anthropometric measurements data of investigated groups: BMI > 30 (n = 36), CKD (n = 14)
and control (n =25)
BMI > 30(1) CKD(2) Control(3) p
N = 36 N = 14 N = 25
Mean ± SD Mean ± SD Mean ± SD
Median (range) Median (range) Median (range)
Age [years] 52,6 ± 8,4 66,8 ± 9,9 53,2 ± 10,5 1-2 p = 0,0009
1-3 p = 0,9672
2-3 p = 0,0015
Weight [kg] 102,5 ± 14,8 79,2 ± 15,3 68,1 ± 10,6 1-2 p = 0,0003
1-3 p = 0,0001
2-3 p = 0,1200
BMI [kg/m2] 34,9 ± 4,5 27,7 ± 4,4 23,9 ± 2,8 1-2 p = 0,0002
1-3 p = 0,0001
2-3 p = 0,0598
Waist circumference [cm] 113,1 ± 11,6 100,5 ± 13,5 81,4 ± 9,6 1-2 p = 0,0168
1-3 p = 0,0001
2-3 p = 0,0003
Serum fasting glucose [mg/dl] 99,5 ± 14,2 100,6 ± 24,0 83,5 ± 8,4 1-2 p = 0,9807
1-3 p = 0,0011
2-3 p = 0,0103
Total cholesterol[mg/dl] 195,1 ± 40,5 198,4 ± 35,1 210,4 ± 48,9 p = ns
HDL [mg/dl] 47,5 ± 13,4 49,6 ± 14,9 59,8 ± 19,6 1-2 p = 0,9360
1-3 p = 0,0225
2-3 p = 0,2184
TG [mg/dl] 126 (57 – 1242) 119 (61 – 1242) 96 (54 – 142) 1-2 p = 1,0000
1-3 p = 0,0040
2-3 p = 0,1264
Serum uric acid [mg/dl] 5,72 ± 1,11 7,26 ± 2,21 4,52 ± 0,96 1-2 p = 0,0092
1-3 p = 0,0059
2-3 p = 0,0001
CRP [ng/l] 2,36 (0,27-106) 2,43 (0,20-41,9) 0,70 (0,11-17,81) 1-2 p = 1,0000
1-3 p = 0,0016
2-3 p = 0,0167
eGFR (MDRD equation) [ml/min] 95,1 ± 15,2 52,4 ± 21,0 98,5 ± 19,6 1-2 p = 0,0001
1-3 p = 0,7730
2-3 p = 0,0001
Serum creatinine[mg/dl] 0,81 ± 0,19 1,35 ± 0,38 0,78 ± 0,18 1-2 p = 0,0001
1-3 p = 0,9230
2-3 p = 0,0001
Urine uric acid mg/24 h 665 ± 350 340 ± 121 535 ± 196 1-2 p = 0,0070
1-3 p = 0,2217
2-3 p = 0,1507
Urine sodium mmol/l 135,9 ± 52,3 87,0 ± 39,9 96,6 ± 44,1 1-2 p = 0,0222
1-3 p = 0,0129
2-3 p = 0,8552
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Table 1 Laboratory and anthropometric measurements data of investigated groups: BMI > 30 (n = 36), CKD (n = 14)
and control (n =25) (Continued)
Urine sodium g/24 h 5,50 ± 2,22 4,15 ± 2,29 3,87 ± 1,52 1-2 p = 0,1865
1-3 p = 0,0157
2-3 p = 0,9310
Microalbuminuria/g creatinine 4,8 (1,3-830) 41,3 (3,7-2656) 4,2 (2,3-10,1) 1-2 p = 0,0146
1-3 p = 1,0000
2-3 p = 0,0021
Abbreviations and explanations: BMI – body mass index, HDL-high density cholesterol, TG –triglicerides, CRP- C reacting protein, NAG - N-acetyl-β-(D)-glucosaminidase,
TNFα -tissue necrosis factor-α, TGFβ- tissue growth factor-β, iNOS- inducible nitric oxide synthase, eNOS- endothelial nitric oxide synthase, p < 0,05 –statistically significant.
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from all participants of the study.
Statistical analysis
Results are expressed as mean ± SD. Data were com-
pared using Mann–Whitney non-parametrical tests. For
all tests p value <0.05 was considered as statistically
significant.
Results
Laboratory data and anthropometric measurements in
subjects with metabolic syndrome (BMI > 30), CKD and
control groups are presented in Table 1 and Additional
file 1: Table S1. As expected, subjects with CKD had
lower eGFR and more microalbuminuria than healthy
controls, and subjects with metabolic syndromes had
worse lipid profiles and higher BMI compared to healthy
subjects. Levels of inflammatory mediators and target
organ injury were also greater in the subjects with meta-
bolic syndrome and CKD compare to healthy controls
(Additional file 1: Table S1). Carotid intimal medial
thickness (IMT) was highest in CKD patients which may
indicate advanced vascular lesions in that population.
Blood pressure measurements in various study groups
were presented in Table 2.
Uric acid
Serum uric acid increased during the FTT in all three
groups, peaking at approximately 60 minutes (Figure 1).Table 2 ABPM measurements in various study groups: BMI > 3
BMI > 30(1) CKD(2)
N = 36 N = 14
Mean ± SD Mean ±
Median (range) Median
SBP[ABPM -24 h] 128,5 ± 12,1 138,8 ± 2
DBP [ABPM-24 h] 76,3 ± 9,4 79,9 ± 6,
Abbreviations: SBP –systolic blood pressure, DBP-diastolic blood pressure, ABPM –a
(1) means - BMI> 30 group; (2) means - CKD group; (3) means - control group.At each time point, serum uric acid was higher in the
subjects with metabolic syndrome and the subjects with
CKD compared to healthy controls (Table 3). Neverthe-
less, the absolute increase in serum uric acid was not
different among groups, although it tended to be highest
in the healthy controls. This was reflected by a greater
percent change in serum uric acid in the healthy con-
trols compared to the CKD and metabolic syndrome
groups (Table 3).
We had hypothesized that the degree of rise in serum
uric acid might correlate with the baseline phenotype of
the individual. However, there was no relationship be-
tween changes in uric acid with any of the baseline clinical
parameters in our study, including eGFR, microalbumi-
nuria, or markers of metabolic syndrome (systolic and dia-
stolic blood pressure, serum triglycerides, serum HDL
cholesterol, fasting blood glucose, or BMI), inflammation
or target organ injury (see Table 4).
Discussion
The ability of fructose to increase serum uric acid was
discovered in the 1960s, and could be quantified by a
“fructose tolerance test” in which an oral dose of fruc-
tose is followed by serial measurements of serum uric
acid [15-21]. Subsequent studies showed that the in-
crease in serum uric acid was increased in subjects re-
ceiving a high fructose diet, and could be reduced by
dietary fructose restriction [13]. Here we examined the
effect of fructose on the uric acid response of subjects0 (n = 36), CKD (n = 14) and control (n = 25)
Control(3) p
N = 25
SD Mean ± SD
(range) Median (range)
2,9 122,1 ± 9,5 1-2 p = 0,1345
1-3 p = 0,2416
2-3 p = 0,0066
8 73,5 ± 4,4 p = ns




















Figure 1 Changes in URIC ACID concentration during FTT in BMI>30; CKD, and control group.
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chronic kidney disease, and healthy controls. Our hy-
pothesis was that subjects with CKD or obesity/meta-
bolic syndrome might show a relatively greater increase
in serum uric acid compared to healthy controls. This is
because there is some evidence that subjects who are
overweight or insulin resistant are more sensitive to the
metabolic effects of fructose [22,23]. In addition, uric
acid is known to regulate fructokinase [24], the principal
enzyme driving fructose metabolism, and hence weTable 3 Comparison of investigated groups following admini
BMI > 30(1)
Mean ± SD
URIC ACID (FTT) 0 5,72 ± 1,11
URIC ACID (FTT) +30 min 6,53 ± 1,30
URIC ACID (FTT) +60 min 6,68 ± 1,29
URIC ACID (FTT) +120 min 6,53 ± 1,22
AUC for URIC ACID 778 ± 148
% Δ (URIC ACID60 vs URIC ACID 0) 17,0 ± 8,9
(1) means - BMI>30 group; (2) means CKD group; (3) means - control group.expected a greater metabolic response to fructose in
subjects with CKD or metabolic syndrome in which
baseline uric acid levels tend to be higher than in healthy
controls.
The principal findings, however, could not confirm the
hypothesis. We did see higher baseline uric acid levels in
both subjects with obesity/metabolic syndrome or CKD,
and following an oral fructose load the uric acid levels
rose further, peaking at 30 to 60 minutes (Figure 1). In-
deed, absolute values of uric acid were always higher instration of fructose (FTT)
CKD(2) Control(3) p
Mean ± SD Mean ± SD
7,26 ± 2,21 4,52 ± 0,96 1-2 p = 0,0092
1-3 p = 0,0059
2-3 p = 0,0001
8,03 ± 2,24 5,68 ± 1,15 1-2 p = 0,0240
1-3 p = 0,1076
2-3 p = 0,0003
8,08 ± 2,19 5,73 ± 1,02 1-2 p = 0,0300
1-3 p = 0,0542
2-3 p = 0,0002
8,02 ± 2,27 5,46 ± 1,05 1-2 p = 0,0196
1-3 p = 0,0261
2-3 p = 0,0001
954 ± 266 660 ± 123 1-2 p = 0,0203
1-3 p = 0,0403
2-3 p = 0,0002
12,5 ± 10,1 28,3 ± 14,5 1-2 p = 0,5552
1-3 p = 0,0020
2-3 p = 0,0013
Table 4 Linear correlation for ΔURIC ACID 60- URIC ACID 0 in FTT with selected parameters
Parametr CKD Metabolic syndrome Control group
Δ URIC ACID60-URIC ACID0 Δ URIC ACID60-URIC ACID0 Δ URIC ACID60-URIC ACID0
Weight [cm] −0,48 p=,086 −0,31 p=,067 −0,32 p=,125
BMI [kg/m2] −0,39 p=,172 −0,36 p=,032 −0,21 p=,326
Triglicerydes [mmo/l] −0,45 p=,103 −0,35 p=,033 −0,26 p=,208
eGFR [ml/min] 0,12 p=,676 −0,01 p=,969 −0,21 p=,308
IMT [mm] 0,04 p=,902 −0,17 p=,341 −0,05 p=,811
RI −0,07 p=,835 0,34 p=,052 0,07 p=,747
PI −0,03 p=,927 0,34 p=,051 −0,07 p=,761
Abbreviations: IMT- intima media thickness, RI-resistance index PI- pulsatility index. p < 0,05 –statistically significant.
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trols. However, there was no difference in the absolute
increase in uric acid level between the three groups. Fur-
thermore, the healthy controls actually showed a greater
relative percent increase in uric acid compared to the
two other groups.
The significance of these findings remain uncertain. The
relatively less uric acid response in subjects with CKD and/
or metabolic syndrome might reflect blunted xanthine oxi-
dase activity, since uric acid can cause a feedback inhibition
of xanthine oxidase[25]. It is also possible that there could
be an inhibition of AMP deaminase, an upstream enzyme
activated by fructose. AMP deaminase is suppressed by
phosphate, and serum phosphate levels tend to be high in
subjects with CKD [26]. Furthermore, there is the possibil-
ity that fatty liver itself, which is common in subjects with
high uric acid levels, including those with CKD or meta-
bolic syndrome, might also have feedback to block uric
acid generation in response to fructose [27].
It is also possible that the relatively blunted rise in serum
uric acid could reflect differences in urinary uric acid re-
sponses to the fructose. Baseline studies did show that the
subjects with metabolic syndrome had higher urinary so-
dium levels, and high urinary sodium can increase uric
acid excretion. However, we administered the fructose tol-
erance test after an overnight fast and no subjects received
salt during this time. However, we do recognize that a
limitation of our study is that we did not measure urinary
uric acid excretion during the fructose tolerance test, so it
is possible this could explain the relatively blunted rise in
uric acid in our subjects with metabolic syndrome. Like-
wise, it is also known that subjects with CKD show in-
creased gut excretion of uric acid, and a compensatory
mechanism could also be operative in these subjects.
We also tested the hypothesis that the degree of
change in uric acid with the fructose tolerance test
might correlate with metabolic, inflammatory, renal or
target organ injury in these subjects. However, this was
not observed. We conclude that the fructose tolerance
test is unlikely to be able to be used as a way to predict
the metabolic phenotype of the patient.While these studies suggest a limited usefulness of the
fructose tolerance test, the potential importance of fructose
as a mediator of kidney disease or metabolic syndrome
should not be dismissed based on the current study. In-
deed, recently our group evaluated the effect of dietary
fructose restriction for 6 weeks in subjects with CKD stage
2 and 3. Our principal finding was that low fructose diet re-
duced blood pressure in those with a “dipping” pattern, as
well as fasting serum insulin and CRP levels. There was also
a nonstatistical reduction in serum uric acid [10].
Conclusions
Subjects with CKD and/or metabolic syndrome have
higher baseline serum uric acid compared to healthy
controls, and both groups show an increase in serum
uric acid following a fructose tolerance test. While the
absolute values of uric acid are higher during the fruc-
tose tolerance test, the change in serum uric acid levels
is similar to that observed in healthy controls, and the
relative percent increase in serum uric acid is actually
higher in healthy controls. Indeed, the change in serum
uric acid with fructose did not correlate with the baseline
phenotype of the subjects, which included evaluation of
metabolic, renal, inflammatory and target organ injury
markers. While these studies suggest that the use of the
fructose tolerance test is likely to be of limited value in
subjects with metabolic syndrome or CKD, they do not
dispute the potential importance of long-term fructose in-
take on metabolic syndrome or kidney disease.
Additional file
Additional file 1: Table S1. Laboratory data, inflammatory markers and
target organ damage indices. Comparison of investigated group: BMI>30
(n=36), CKD (n=14) and control (n=25).
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